|
목적 : To analyze the subfoveal choroidal thickness (SFChT) changes in resolved idiopathic central serous chorioretinopathy (CSC) and the association between SFChT changes and recurrence rate.
방법 : 113-CSC eyes which were completely resolved after treatment were included this study: 41-eyes with intravitreal bevacizumab injection (IVB), 28-eyes with half-fluence photodynamic therapy (H-PDT), 14-eyes with focal laser photocoagulation (LP), 30-eyes with spontaneous resolution (SR). The baseline characteristics of each group were compared. And the amount of SFChT thinning in each group was analyzed. We also analyzed whether the different amount of SFChT thinning after anatomical resolution could affect final BCVA and the recurrence rate of CSC.
결과 : Baseline LogMAR BCVA of IVB, H-PDT, LP and SR were 0.14, 0.12, 0.26 and 0.04, respectively. Baseline SFChT of IVB, H-PDT, LP and SR were 449.8, 462.5 and 397.6 and 385.5 µm, respectively. Baseline BCVA and SFChT were significantly improved and reduce, respectively, after resolution in all groups. SFChT thinning after IVB, H-PDT, LP and SR was 68.8, 77.5 and 28.6 and 25.0 µm, respectively. Recurrence was not significantly different between each treatment. However, amount of SFChT thinning was significantly related to recurrence (Odd ratio; 0.957, p-value; 0.003) and was not related to BCVA.
결론 : SFChT was significantly reduced after complete resolution of SRF, regardless of treatment modality. The SFChT changes of IVB and H-PDT after resolution was significantly larger than that of SR and LP. Eyes with larger SFChT thinning after treatment tended not to recur after anatomical resolution.
|